Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term maintenance and extension study of upadacitinib in Crohn's disease after M14-431 or M14-433
MOH_2018-05-29_002232Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in Crohn's disease (6 arms), sponsored by AbbVie Inc. Started May 2018; status: active, not recruiting.
02
Drugs
upadacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2018-05-29_002232.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-05-29_002232.